Topic resource collection
Approved comparison material connected to this topic.
9 resourcesRead both sides
Survodutide Phase 3 NASH, Obesity 48% histological NASH resolution vs 12% placebo; 52% liver fat reduction 72 weeks p<0.001 for primary endpoint First dual-agonist to achieve fibrosis improvement in Phase 3. Regulatory filing exp…
Mitochondrial-targeting (SS-31 analogs) Cardiolipin binding, cristae stabilization Subcutaneous injection FDA-approved (Nov 2026) Blood-brain barrier penetration previously thought impossible First mitochondrial peptide to achiev…
Triple Receptor Agonist GLP-1/GIP/Glucagon 24.7% weight loss at 28 weeks (vs 20.9% tirzepatide baseline) Glucagon engagement drives thermogenesis without muscle catabolism Obesity + T2DM treatment ceiling raised significantly Thi…
Nature Neuroscience, July 8 Stanford Medicine Dihexa HGF pathway activation at 0.5 mg/kg protects dopaminergic neurons from oxidative stress Neuroprotection occurs at 40% lower concentration than cognitive enhancement threshold. …
CNS-Active Peptides Stanford, Johns Hopkins, UC San Diego Lipidated Dihexa analogues: 4.2× BBB penetration; cerebrolysin mechanism mapped; P21 cognitive improvement in MCI Phase 2 (P21 complete); Phase 1 (lipidated Dihexa analogu…
The following table summarizes the three major peptide categories that dominated September 2026 research developments, their mechanisms, clinical milestones, and research implications. Dual-Receptor Metabolic Agonists Survodutide…
Survodutide GLP-1/glucagon dual agonist 18.6% mean body weight reduction at 72 weeks; 12–14% RMR increase sustained without appetite escalation Adults with obesity (BMI ≥30) or overweight with comorbidity Phase 3 (SYNCHRONIZE tri…
Tirzepatide GIP/GLP-1 dual agonist 23.1% body weight reduction 104 weeks Exceeds single-pathway GLP-1 outcomes by 35–40%; rivals bariatric surgery without invasion Survodutide GLP-1/glucagon dual agonist 18.7% weight loss, 92% le…
Before selecting peptides for metabolic, cognitive, or immune research protocols, understanding mechanism-specific advantages across compound classes prevents mismatched applications and wasted resources. Survodutide Dual GLP-1/g…